QVC pays for FTC violations
This article was originally published in The Tan Sheet
Executive Summary
The U.S. District Court for the Eastern District of Pennsylvania orders the home shopping channel to pay $1.5 million in civil penalties and $6 million for consumer redress to the Federal Trade Commission for using deceptive advertising practices to market weight-loss supplements such as Bee-Alive Feel Good 90-Day System and For Women Only Zero Fat Ultra. The consent decree entered by the court March 4 further enjoins the Liberty Media subsidiary from again violating FTC's initial 2000 order, which bars QVC from making structure/function claims for dietary supplements without supportive scientific evidence. The commission filed its complaint against West Chester, Pa.-based QVC in 2004 (1"The Tan Sheet" March 29, 2004, In Brief)
You may also be interested in...
FTC goes after QVC
The home shopping channel violated a previous final order prohibiting QVC from using deceptive advertising practices to market weight-loss products, the FTC alleges in a March 24 complaint filed in Eastern Pennsylvania federal court. The commission maintains each airing of programs for Bee-Alive, For Women Only, Lipofactor Cellulite Target Lotion and Lite Bites a violation of the previous order. Programs touted testimonials from patients with cancer, lupus and multiple sclerosis who also claimed to have lost between 30 lbs and 140 lbs. In a same-day 1release, FTC points out the "claims for these products are not only unsubstantiated, but for some, scientifically impossible." Agency seeks monetary civil penalties, consumers redress and to permanently enjoin the Comcast subsidiary from violating the June 2000 order...
First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.
ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach
Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.